Flowsion Earns CE Mark for Glucose Control Device

Denmark-based Flowsion has received the CE mark for its Glycostat automated glucose control system for use in intensive care units.

The system is designed to closely monitor blood glucose levels in patients under intensive care and to provide appropriate alarms for hypoglycemic or hyperglycemic readings.

Glucose control is a persistent problem for intensive care units worldwide, noted the company’s CEO Hans Jorgen Pedersen, who claimed the automated system can help increase survival rates and lower treatment costs at the same time.